Gilead Sciences has won a lawsuit in Delaware where a jury ruled that the company’s HIV prevention drugs
Share: email Subscribe
Weekly Top Stories Tue, 16 May 2023
We have 22 articles this week, #Hoth Therapeutics and #Algorithm Sciences Terminate Letter of Intent to Merge. #Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business. #Genesis Drug Discovery & #Development (GD3), a Member of Genesis Global Group, Acquires JSS Medical Research to Expand its Clinical Services Portfolio #Probo Medical Completes Acquisition of National Ultrasound. #Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion #Wearable company Oura acquires digital identification startup Proxy.
Editor's Choice
1. 
 Gilead Wins HIV Patent Suit, Nabs Oncology, and Inflammation Startup
2. 
 New AI Tools Predict Parkinson’s Onset, Heart Attack Risk After Surgery, and More Briefs
3. 
 Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
4. 
 Lucem Health Secures $7.7M for Agnostic AI-Powered Platform
5. 
 Bioventus Announces Divestiture of its Wound Business
Top 10 M&A Transactions
6. 
 Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge
7. 
 Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
8. 
 Genesis Drug Discovery & Development (GD3), a Member of Genesis Global Group, Acquires JSS Medical Research to Expand its Clinical Services Portfolio
9. 
 Probo Medical Completes Acquisition of National Ultrasound
10. 
 Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion
11. 
 Wearable Company Oura Acquires Digital Identification Startup Proxy.
12. 
 LifeNet Health Acquires Bioventus Wound Care Division
13. 
 MultiPlan Acquires Benefits Science LLC for $160M
14. 
 Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
15. 
 Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
Top 4 Venture Funding
16. 
 Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $694 Million of Initial Proceeds
17. 
 Syneos Taken Private for $4.46 bln by Investment Consortium
18. 
 Amino Health Secures $80M for Healthcare Guidance Platform
19. 
 Sobi Expands Hematology Portfolio with $1.7B Buy of CTI
Top 2 Partnerships Announcements
20. 
 Teladoc Health, HealthJoy Expand Partnership to Include Virtual Primary Care
21. 
 NeuroFlow, Emory Healthcare Partner to Support Psychiatric Care
Read More Corporate Development and M&A Activity
Get Featured: Send us your article or blog and we will feature it on our publication, reach over thousands of executives. Click Here.
Editor: Ed Francis

Ed has more than 25 years of management consulting experience and currently is the Global Managing Partner for Infosys Consulting Health and Life Sciences business guiding some of the industry's most prominent health and life sciences organizations through complex transformations.

If you need help with your complex transformation whether it be M&A, digital, or strategic cost reduction or need to bring more innovation into your business strategy Ed can be contacted at Edward.Francis@infosys.com and +1-847-910-6073

Or connect with him at

OTHER ADVISORIES

Health Plan Hospital IT
IT GovHealth
Retail POP Health
Ageing Life Sciences

Advertise with us

We Reach Half Million Decision Makers in:
Healthcare · IT · Retail · Industrial
Advertise with us and reach the right audience.
advertise@distilnfo.com

Contact Us

5760 Legacy Dr, B3-405,
Plano TX 75024
+1 469-270-3311

DistilINFO Publications

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you - saving time and keeping you up to date on your interest areas.

You are receiving this newsletter because you are subscribed to one or more DistilINFO Publications Newsletter/s. If you feel this email was sent by mistake or you want to opt out, you can unsubscribe.

View in browser | Advertise | Contact Us